

CHARLES D. BAKER Governor

KARYN E. POLITO Lieutenant Governor

MARYLOU SUDDERS Secretary The Commonwealth of Massachusetts Executive Office of Health and Human Services One Ashburton Place, Room 1109 Boston, Massachusetts 02108

> Tel: (617) 573-1600 Fax: (617) 573-1891 www.mass.gov/eohhs

Administrative Bulletin 20-06

101 CMR 320.00 Clinical Laboratory Services

Effective January 1, 2020

Procedure Code Update

Pursuant to 101 CMR 320.01(3), the Executive Office of Health and Human Services is adding new procedure codes for clinical laboratory services. As set forth in 101 CMR 320.01(3)(c), the rates for newly added codes are calculated according to the rate methodology used in setting clinical laboratory rates. Added codes without Medicare fees are reimbursed at individual consideration (I.C.). Rates listed in this administrative bulletin are applicable until revised rates are issued by the EOHHS.

The changes, effective January 1, 2020, are as follows.

CODE	CHANGE	RATE	DESCRIPTION
80145	Addition	\$28.50	Adalimumab
80187	Addition	\$20.03	Posaconazole
80230	Addition	\$28.50	Infliximab
80235	Addition	\$20.03	Lacosamide
80280	Addition	\$28.50	Vedolizumab
80285	Addition	\$20.03	Voriconazole
81277	Addition	\$857.12	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities

CODE	CHANGE	RATE	DESCRIPTION
81307	Addition	\$209.02	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence
81308	Addition	\$222.67	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant
81309	Addition	\$203.07	PIK3CA (phosphatidylinositol-4, 5-biphosphate 3- kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)
81522	Addition	\$2,861.76	Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score
81542	Addition	I.C.	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score
81552	Addition	I.C.	Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis
87563	Addition	\$25.93	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma genitalium, amplified probe technique